Skip to main content
OpenTrials
Completed

NCT Number: NCT02148718

Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease

The purpose of this study is to evaluate the rapidity of onset of clinical response to adalimumab therapy in patients with luminal Crohn's disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Moderate to Severe Crohn's Disease Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Crohn's disease (CD) diagnosed within, at least, the previous 4 months.
  • Patients with active luminal (Harvey-Bradshaw Index [HBI] ≥ 8) moderate to- severe CD.
  • No response to a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant.
  • If receiving any of the following treatments, their dose should be stable during the periods indicated:
  • Aminosalicylates for, at least, the last 4 weeks
  • Probiotics for, at least, the last 4 weeks
  • Analgesics for, at least, the last 4 weeks
  • Antidiarrheals for, at least, the last 4 weeks
  • CD-related antibiotics for, at least, the last 4 weeks
  • Azathioprine, 6-mercaptopurine or methotrexate for, at least, the last 12 weeks
  • If receiving any of the following treatments, their dose should not have been increase in the past two weeks (the dose reduction is permitted):
  • Oral budesonide (maximum dose of 9 mg/day)
  • Oral prednisone or equivalent (maximum dose of 40mg/day)

Exclusion criteria

  • Previous treatment with any anti-Tumor Necrosis Factor agent
  • Surgical bowel resection within the previous 6 months, ostomy, extensive bowel resection (> 100 cm), short bowel syndrome
  • Fistulising Crohn's disease
  • Treatment with cyclosporine or tacrolimus within the previous 8 weeks
  • Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from screening, congestive heart failure of worse than grade II New York criteria (New York Heart Association Functional Classification).
  • Subject with an ostomy or ileoanal pouch, proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis (Subjects with a previous ileo-rectal anastomosis are not excluded).
  • Screening laboratory values (according to central laboratory)
  • Known hepatitis C (HC) infection.
  • Serologic evidence of hepatitis B (HB) infection based on the results of testing for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc) and hepatitis B surface antibody (anti-HBs) antibodies.

Treatment and study plan

Adalimumab

Biological

Adalimumab pre-filled syringe, administered by subcutaneous injection

Other names: Humira, ABT-D2E7

Primary outcomes

  1. Percentage of Participants With Clinical Response at Day 4

    Time frame: Day 4

    Clinical response defined as a decrease of at least 3 points in Harvey-Bradshaw Index (HBI) score. The HBI consists of only clinical parameters (general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and complications): The first 3 items are scored for the previous day. Patients with Crohn's disease who scored 3 or less on the HBI are very likely to be in remission. Patients with a score of 8 to 9 or higher are considered to have severe disease.

Secondary outcomes

  1. Percentage of Participants With Clinical Response at Week 1

    Time frame: Week 1

    Clinical response defined as a decrease of at least 3 points in HBI score. The HBI consists of only clinical parameters (general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and complications): The first 3 items are scored for the previous day. Patients with Crohn's disease who scored 3 or less on the HBI are very likely to be in remission. Patients with a score of 8 to 9 or higher are considered to have severe disease.

  2. Percentage of Participants With Clinical Remission at Weeks 2 and 4

    Time frame: Weeks 2 and 4

    Clinical remission defined as HBI < 5. The HBI consists of only clinical parameters (general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and complications): The first 3 items are scored for the previous day. Patients with Crohn's disease who scored 3 or less on the HBI are very likely to be in remission. Patients with a score of 8 to 9 or higher are considered to have severe disease.

  3. European Quality of Life (EuroQol) 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) Index Score: Change From Baseline to Week 12

    Time frame: Baseline (Week 0) and Week 12

    The EQ-5D-3L is a standardized instrument for use as a measure of health-related quality of life (HRQoL) and consists of 2 components:

    • The EQ-5D-3L Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with 3 levels of severity for each dimension ('no problems', 'some problems', and 'extreme problems'). The level of severity reported on each of the EQ-5D-3L dimensions determines a unique health state. Health states are converted into a weighted health state index. These weights lie on a scale on which full health has a value of 1 and dead has a value of 0.
    • The EQ-5D visual analog scale (VAS) is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively.

    A positive change represents an improvement in HRQoL. Mean Baseline and mean change from Baseline to Week 12 in the EQ-5D-3L Index Score are presented.

  4. European Quality of Life (EuroQol) 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) Visual Analog Scale (VAS): Change From Baseline to Week 12

    Time frame: Baseline (Week 0) and Week 12

    The EQ-5D-3L is a standardized instrument for use as a measure of HRQoL and consists of 2 components:

    • The EQ-5D-3L Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with 3 levels of severity for each dimension ('no problems', 'some problems', and 'extreme problems'). The level of severity reported on each of the EQ-5D-3L dimensions determines a unique health state. Health states are converted into a weighted health state index. These weights lie on a scale on which full health has a value of 1 and dead has a value of 0.
    • The EQ-5D VAS is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively.

    A positive change represents an improvement in HRQoL. Mean Baseline and mean change from Baseline to Week 12 in the EQ-5D-3L VAS are presented.

  5. Inflammatory Bowel Disease Quality-36 (IBDQ-36) Questionnaire Overall Score: Change From Baseline to Week 12

    Time frame: Baseline (Week 0) and Week 12

    The IBDQ-36 is used to assess the HRQoL related to bowel symptoms. The IBDQ-36 overall score is calculated as the sum of thirty-six items, each scored on a 1 to 7 likert point scale, and ranges from 7 to 252. The highest score indicates the best HRQoL related to bowel symptoms. A positive change in IBDQ-36 overall score indicates an improvement in HRQoL due to inflammatory bowel disease. Mean Baseline and mean change from Baseline to Week 12 in the EQ-5D-3L VAS are presented.

  6. Fatigue Impact Scale for Daily Use (D-FIS): Change From Baseline to Week 12

    Time frame: Baseline (Week 0) and Week 12

    The D-FIS is used to measure the impact of fatigue on the daily lives of persons. The D-FIS overall score was calculated as the sum of eight items, each scored on a 0 to 4 point scale, and ranges from 0 to 32. A higher score indicates a higher impact of fatigue on daily life. A negative change in D-FIS Overall Score means an improvement in HRQoL due to fatigue. Mean Baseline and mean change from Baseline to Week 12 are presented.

  7. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Hemoglobin

    Time frame: Baseline (Week 0) and Week 12

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes sedimentation rate (ESR), C-reactive protein (CRP), fecal calprotectin, and coagulation (activated partial thromboplastin time [aPTT], international normalized ratio [INR], and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 are presented.

  8. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Hematocrit

    Time frame: Baseline (Week 0) and Week 12

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

  9. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, and Platelets

    Time frame: Baseline (Week 0) and Week 12

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

  10. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Erythrocytes

    Time frame: Baseline (Week 0) and Week 12

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

  11. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Sedimentation Rate (ESR)

    Time frame: Baseline (Week 0) and Week 12

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

  12. Change From Baseline to Week 12 in Analytic Markers of Inflammation: C-reactive Protein (CRP)

    Time frame: Baseline (Week 0) and Week 12

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

  13. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Fecal Calprotectin

    Time frame: Baseline (Week 0) and Week 12

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

  14. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Activated Partial Thromboplastin Time (aPTT)

    Time frame: Baseline (Week 0) and Week 12

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

  15. Change From Baseline to Week 12 in Analytic Markers of Inflammation: International Normalized Ratio (INR)

    Time frame: Baseline (Week 0) and Week 12

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

  16. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Fibrinogen

    Time frame: Baseline (Week 0) and Week 12

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

  17. Percentage of Participants With Clinical Response at Day 4 or Week 12 and Clinical Remission at Week 12

    Time frame: Up to Week 12

    The percentage of participants with clinical response (defined as decrease of at least 3 points in HBI score) at Day 4 or Week 1 and clinical remission (defined as a HBI < 5) at Week 12.

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Collaborators

  • Laboratorio Echevarne
  • Pivotal S.L.

Registry information

Official study title

Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study)

Acronym: RAPIDA

Important dates

Study start
2014
Primary completion
2016
Study completion
2017
First posted
May 28, 2014
Registry last updated
Mar 1, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.